ABG Sundal Collier acted as sole manager in the private placement of new shares in APIM Therapeutics AS enabling the company to enter Phase 2 clinical development

On 18 May 2021, APIM Therapeutics, an oncology focused biotechnology company developing innovative anti-cancer treatments targeting stress responses in tumor cells, announced the completion of a private placement directed towards existing and certain new investors in the company.
The company is looking forward to embarking on the next steps of clinical development of its first-in-class, lead compound, ATX-101. With the proceeds from the private placement, the company will initiate a proof-of-concept combination study in recurrent ovarian cancer and support a Phase-2 investigator-initiated study in sarcoma.